Skip to main content

Medavie Blue Cross has also seen a significant decline in new patient starts for hepatitis C medications, says Chris Goguen, the insurer’s strategic pharmaceutical partnerships lead in Moncton, N.B. Demand is now one-fifth of the volume it was a year-and-a-half ago, although there may be a slight bump if and when the medications are approved for more indications, says Christine Than, a pharmacist and drug solutions specialist at Aon Hewitt in Montreal.

Click here to read the full article

Share this post

About the Author
Chris Goguen

Chris joined Medavie Blue Cross in 2015, with 25 years of experience as a senior leader within the research-based pharmaceutical industry in Canada. With the majority of his career focussed on External Affairs, including strategy and relationship development with governments, private payers & other health stakeholders across Canada, Chris has developed expertise in drug pricing, access, negotiation and patient health management strategies. He has played a lead role in development and implementation of numerous disease [drug] management partnership programs, impacting both public and private health system outcomes.  

View all posts